The CD58 (LFA-3) and HLA-DR expression intensity on leukemic cells of 53 adult patients with AML M1 and M2 was determined. Also the relation between these expressions and the achievement remission in patients was searched. Two quantitative flow cytometry methods of the expression intensity analysis of CD58 and HLA-DR antigens were performed. The analysis indicated that myeloblasts at diagnosis of patients with post chemotherapy remission (CR+) showed higher of both CD58 and HLA-DR intensity expression as compared to patients with no remission (CR-) despite intensive chemotherapy (p< 0.01). Our results indicated that high expression intensity of studied molecules on leukemic myeloblasts might be beneficial factor for anti-leukemic activity of lymphocytes T and NK cells. Additionally, the level of expression CD58 and HLA-DR may be useful element in the AML remission prognosis.